Clinical Trial Update: Real-World Treatment Study of Koselugo (Selumetinib)

View source ↗

Summary

AstraZeneca is conducting a real-world study of Koselugo (selumetinib) that is currently recruiting for neurofibromatosis type 1 and plexiform neurofibroma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• Koselugo (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Neurofibromatosis 1, Neurofibroma, Plexiform | Status: RECRUITING